Rigel CFOs Performance-Based Option Vesting Confirms 7,394-Share Ownership
Rhea-AI Filing Summary
Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, was granted a performance-based employee stock option covering 7,394 shares of common stock with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The option was originally granted on January 29, 2025 with an expiration date of January 29, 2035. Because the grant was subject to a performance-based vesting condition, it became reportable only after the company determined the performance metric was satisfied on September 15, 2025, at which point the option fully vested. Following the determination, the reporting shows 7,394 shares underlying the option beneficially owned, held directly. The Form 4 was signed by an attorney-in-fact and filed on September 17, 2025.
Positive
- Performance-based vesting was achieved, showing executive compensation tied to measurable goals
- Exercise price set at closing market price on the grant date ($22.49), indicating grant pricing aligned with shareholder value at grant
- Full vesting confirmed for 7,394 shares, clarifying the executive's current beneficial ownership position
Negative
- None.
Insights
TL;DR: A routine, performance-vested option for the CFO became exercisable, reflecting compensation tied to company performance rather than immediate insider buying or selling.
This Form 4 reports the vesting of a performance-based stock option covering 7,394 shares at an exercise price of $22.49 granted on January 29, 2025, expiring January 29, 2035. The vesting occurred when a specified performance metric was met on September 15, 2025. The filing does not show an exercise, sale, or cash proceeds; it records a change in beneficial ownership due to vesting. For investors, this is a compensation-related event that signals alignment of executive pay with stated performance criteria but does not by itself alter the companys reported cash position or indicate immediate insider liquidity.
TL;DR: The disclosure documents a standard performance-vesting event for a senior executive, consistent with governance practices tying pay to metrics.
The document indicates Rigel used performance-based equity to incentivize its CFO, with the grant priced at the closing market price on the grant date. Vesting was contingent on a measurable performance condition and was formally recognized when that condition was certified on September 15, 2025. The Form 4 was timely filed and signed via attorney-in-fact. The filing contains no indication of policy breaches, related-party transactions beyond the executive grant, or other governance concerns disclosed in this form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 7,394 | $0.00 | -- |
Footnotes (1)
- The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met.
